Methylated genes in breast cancer: Associations with clinical and histopathological features in a familial breast cancer cohort

Cancer Biology and Therapy

Volumn 11, Issue 10, 2011, Pages 853-865

  Swift Scanlan, Theresa ^a,b   Vang, Russell ^b   Blackford, Amanda ^b   Fackler, Mary Jo ^b   Sukumar, Saraswati ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; DNA methylation; Epigenetic; Familial; Methylation specific PCR; Protective; QM MSP; Risk

Indexed keywords

APC PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CYCLIN D2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN RAR BETA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; DNA METHYLATION; FAMILIAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GERM LINE; HIN1 GENE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; TWIST ONCOGENE;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; DNA METHYLATION; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS;

EID: 79957438722     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.10.15177     Document Type: Article

References (68)

1. Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet 2010; 86:420-33.
2. Jin W, Chen L, Chen Y, Xu SG, Di GH, Yin WJ, et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat 2010; 123:359-73.
3. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, et al. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 2008; 19:1870-4.
4. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al. Estrogen receptor alpha, BRCA1 and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 2008; 111:113-20.
5. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006; 12:3306-10.
6. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64:3807-13. (Pubitemid 38697289)
7. Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77:833-8. (Pubitemid 28378129)
8. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105:14867-72.
9. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006; 310:251-74. (Pubitemid 47400293)
10. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239-59.
11. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15:5-17.
12. Barba M, McCann SE, Nie J, Vito D, Stranges S, Fuhrman B, et al. Perinatal exposures and breast cancer risk in the western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2006; 17:395-401.
13. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407-27.
14. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40:2667-75. (Pubitemid 39574720)
15. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, et al. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2010; In press.
16. Balogh GA, Heulings R, Mailo D, Wang R, Li YS, Hardy R, et al. Methodological approach to study the genomic profile of the human breast. Int J Oncol 2007; 31:253-60.
17. Fackler MJ, Rivers A, Teo WW, Mangat A, Taylor E, Zhang Z, et al. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin Cancer Res 2009; 15:3802-11.
18. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, et al. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther 2008; 7:1398-406.
19. Swift-Scanlan T, Blackford A, Argani P, Sukumar S, Fackler MJ. Two-color quantitative multiplex methylation-specific PCR. Biotechniques 2006; 40:210-9. (Pubitemid 46542642)
20. Jones PA, Laird PW. Cancer epigenetics comes of age. NatGenet 1999; 21:163-7. (Pubitemid 29070360)
21. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 2007; 67:194-201. (Pubitemid 46142775)
22. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001; 93:1465-72. (Pubitemid 32982675)
23. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 2008; 6:1365-74.
24. Gort EH, Suijkerbuijk KP, Roothaan SM, Raman V, Vooijs M, van der Wall E, et al. Methylation of the TWIST1 promoter, TWIST1 mRNA levels and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:3325-30.
25. Okada T, Suehiro Y, Ueno K, Mitomori S, Kaneko S, Nishioka M, et al. TWIST1 hypermethylation is observed frequently in colorectal tumors and its over-expression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer 2010; 49:452-62.
26. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med 2006; 84:911-8. (Pubitemid 44655869)
27. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001; 61:2782-7. (Pubitemid 32685869)
28. Tapia T, Smalley SV, Kohen P, Munoz A, Solis LM, Corvalan A, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 2008; 3:157-63.
29. Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000; 36:2294-300.
30. Lee MN, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2 and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007; 13:832-8.
31. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62:2455-61. (Pubitemid 34462717)
32. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, et al. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 2005; 113:600-4. (Pubitemid 40038736)
33. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007; 81:280-7. (Pubitemid 47030571)
34. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61:3105-9. (Pubitemid 32691961)
35. Lombaerts M, van WT, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006; 94:661-71. (Pubitemid 43361897)
36. Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, Shapiro CL, et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 2008; 29:1459-65.
37. Pinzone JJ, Stevenson H, Strobl JS, Berg PE. Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol 2004; 24:4605-12. (Pubitemid 38668029)
38. Kim SJ, Kim TW, Lee SY, Park SJ, Kim HS, Chung KW, et al. CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med 2004; 14:289-93.
39. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13:2207-17. (Pubitemid 29426726)
40. Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 1999; 75:566-77. (Pubitemid 29529912)
41. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:927-39. (Pubitemid 38798858)
42. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107:970-5. (Pubitemid 37429839)
43. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003; 16:1095-101. (Pubitemid 37414203)
44. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997; 14:1329-40. (Pubitemid 27151990)
45. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
46. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005; 11:2156-62. (Pubitemid 40490172)
47. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006; 6:48.
48. Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 2006; 66:29-33. (Pubitemid 43166004)
49. Fabianowska-Majewska K, Kordek R, Krawczyk B. Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells. Nucleosides Nucleotides Nucleic Acids 2006; 25:1025-8. (Pubitemid 44651841)
50. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7:1998-2004. (Pubitemid 32994838)
51. Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003; 106:208-15. (Pubitemid 36835173)
52. Muller HM, Widschwendter M. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn 2003; 3:443-58. (Pubitemid 36859292)
53. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20:1509-18. (Pubitemid 32291201)
54. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65:3497-508. (Pubitemid 40616319)
55. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, et al. Promoter hyper-methylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005; 11:166-72. (Pubitemid 40081117)
56. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hyper-methylation in multiple genes in breast cancer. Cancer Res 2004; 64:4442-52. (Pubitemid 38856915)
57. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12:6626-36. (Pubitemid 44876830)
58. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8:38.
59. Kontorovich T, Cohen Y, Nir U, Friedman E. Promoter methylation patterns of ATM ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat 2009; 116:195-200.
60. Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, et al. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res 2007; 9:20.
61. Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, et al. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 2005; 11:1146-53. (Pubitemid 40175764)
62. Loughrey M, Provan PJ, Byth K, Balleine RL. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource. Pathology 2008; 40:352-8.
63. Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascon A, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 2007; 20:1298-306. (Pubitemid 350126855)
64. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003; 100:2532-7. (Pubitemid 36297533)
65. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-7.
66. Sambrook J, Fritsch EF, Mantias T, ed(s). Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
67. Martorell MR, Navarro J, Marquez C, Egozcue J, Benet J. Hypomethylation of human sperm pronuclear chromosomes. Cytogenet Cell Genet 1997; 76:123-7. (Pubitemid 27239154)
68. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6. (Pubitemid 26296693)